Keywords
Preeclampsia
Prevention
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy of prophylactic aspirin use in reducing the incidence of preeclampsia in high-risk pregnant women. Methods: This is an integrative literature review carried out through the PubMED, Virtual Health Library (VHL) and CAPES Periodical databases, using the descriptors: "Aspirin", "Effects", "Pre-Eclampsia", "Prevention" and obtaining the search truncation: (Effects) AND (Aspirin) AND (Prevention) AND (Pre-Eclampsia). A total of 1,122 articles were found, filtered according to inclusion criteria (Portuguese, English and Spanish; period from 2019 to 2024; full articles) and exclusion criteria (duplicate articles, abstracts, out of scope). Results: Aspirin is recommended to improve perinatal outcomes, especially when started between 11 and 16 weeks of gestation. However, adherence to treatment is low, affecting its effectiveness, with up to 50% of pregnant women not following the recommendations. Factors such as lack of information and concerns about adverse effects contribute to this resistance, and although aspirin has shown benefits, there are still challenges, such as resistance to treatment and variations in response. Final considerations: Prophylactic use of aspirin is effective in reducing preeclampsia in high-risk pregnant women. However, further studies are needed to optimize the use of aspirin and maximize its benefits.
References
DEMUTH B. et al. Aspirin at 75 to 81 mg daily for the prevention of preterm pre-eclampsia: Systematic review and meta-analysis. Journal of clinical medicine, 2024; 13(4): 1022.
GARCIA-MANAU P. et al. Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor. Acta obstetricia et gynecologica Scandinavica, 2023; 102(12): 1711–1718.
GHAZANFARPOUR M. et al. Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. Drug discovery today, 2020; 25(8): 1487–1501.
GIL-VILLA, A. et al. Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia. American journal of reproductive immunology, 2020; 83(2): 13207.
GUO K. et al. Low-dose aspirin inhibits trophoblast cell apoptosis by activating the CREB/Bcl-2 pathway in pre-eclampsia. Cell cycle (Georgetown, Tex.), 2022; 21(21): 2223–2238.
HANTOUSHZADEH S. et al. Aspirin administration from early pregnancy versus initiation after 11 weeks of gestation for prevention of pre-eclampsia in high-risk pregnant women: Study protocol for randomized controlled trial. International journal of reproductive biomedicine (Yazd, Iran), 2024; 22(1): 69–80.
HERNANDEZ F. et al. Aspirin resistance in pregnancy is associated with reduced interleukin-2 (IL-2) concentrations in maternal serum: Implications for aspirin prophylaxis for preeclampsia. Pregnancy hypertension, 2024; 37(101131): 101131.
HU X. et al. The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: A network meta-analysis of 23 randomized controlled trials. Journal of clinical hypertension (Greenwich, Conn.), 2024; 26(5): 455–464.
HUAI J. et al. Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2021; 23(5): 1060–1067.
LAILLER G. et al. Aspirin for the prevention of early and severe pre-eclampsia recurrence: A real-world population-based study. Drugs, 2023; 83(5): 429–437.
LAKE E. et al. Obstetric care provider’s knowledge about the use of low dose aspirin for preeclampsia prevention in low and middle income countries: a systematic review and meta-analysis. BMC pregnancy and childbirth, 2024; 24(1): 611.
LANDMAN A. et al. Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. Obstetrical & gynecological survey, 2022; 77(6): 328–329.
LIU J. et al. Aspirin versus metformin in pregnancies at high risk of preterm pre-eclampsia in China (AVERT): protocol for a multicentre, double-blind, 3-arm randomised controlled trial. BMJ open, 2024; 14(4): 74493.
MONTFORT P. et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: A prospective cohort study. Acta Obstet Gynecol Scand, 2020; 99(1): 875–883.
MULDOON K. et al. Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2023; 36(1): 2200879.
REN Y. et al. Application of low dose aspirin in pre-eclampsia. Frontiers in medicine, 2023; 10(1): 1111371.
ROLNIK D. et al. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. American journal of obstetrics and gynecology, 2024; 231(3): 3421-3429.
SHANMUGALINGAM R. et al. Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis. PloS one, 2020: 15(2): 0229622.
SU MT. et al. Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. Journal of hypertension, 2019; 37(12): 2461–2469.
TOLCHER M. et al. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. American journal of obstetrics & gynecology MFM, 2020; 2(4): 100184.
VAN MONTFORT P. et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: A prospective cohort study. Acta obstetricia et gynecologica Scandinavica, 2020; 99(7): 875–883.
VINOGRADOV R. et al. Aspirin non-response in pregnant women at increased risk of pre-eclampsia. European journal of obstetrics, gynecology, and reproductive biology, 2020; 254(1): 292–297.
WALSH SW e STRAUSS JF. The road to low-dose aspirin therapy for the prevention of preeclampsia began with the placenta. International journal of molecular sciences, 2021; 22(13): 6985.
WRIGHT D. et al. When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. American journal of obstetrics and gynecology, 2022; 226(2S): S1120–S1125.
ZHOU L. et al. Evaluation of impacts of aspirin therapy versus placebo on preeclampsia: An observational study. Heliyon, 2023; 9(9): 19527.